L2 DIAGNOSTICS, LLC

Basic Information

BOX 8175
NEW HAVEN, CT, 06530-0175

Company Profile

n/a

Additional Details

Field Value
DUNS: 142406110
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. IGF OT IGF Topic Phase I SBIR Predictive Biomarkers of Adverse Reactions to Prostate Cancer Radiotherapy

    Amount: $271,237.00

    Not Available

    SBIR Phase I 2015 Department of Health and Human Services National Institutes of Health
  2. Therapeutic Inhibition of MIF in Type 1 Diabetes

    Amount: $297,302.00

    DESCRIPTION provided by applicant The long term product goal of this project is a small molecule therapeutic to prevent or treat Type diabetes T D Our objective is to reduce the inflammatory r ...

    SBIR Phase I 2015 Department of Health and Human Services National Institutes of Health
  3. Targeted Inactivation of the CCR5 HIV Coreceptor with Peptide Nucleic Acids

    Amount: $250,298.00

    DESCRIPTION (provided by applicant): Over 34 million people are currently living with HIV/AIDS. Combination antiviral therapies have significantly reduced the morbidity and mortality of the disease; h ...

    SBIR Phase I 2014 Department of Health and Human Services
  4. Sterculic Acid Analogs to Inhibit Macular Degeneration

    Amount: $224,700.00

    ABSTRACT The long-term product goal of this project is a small molecule therapeutic for choroidal neovascularization (CNV, the hallmark of wet age-related macular degradation), an abnormal growth o ...

    SBIR Phase I 2014 Department of Health and Human Services
  5. Measurement of Beta Cell Death in Diabetes

    Amount: $1,348,103.00

    DESCRIPTION provided by applicant All forms of diabetes are characterized by the death of insulin producing cells In Type diabetes T D this leads to the reliance on exogenous insulin for sur ...

    STTR Phase II 2014 Department of Health and Human Services National Institutes of Health
  6. A serologic assay to measure successful Lyme borreliosis antibiotic therapy

    Amount: $1,763,066.00

    DESCRIPTION provided by applicant Lyme disease LD caused by the Ixodes tick borne spirochete Borrelia burgdorferi Bb is the most common vector borne disease in the United States Despite publi ...

    SBIR Phase II 2014 Department of Health and Human Services National Institutes of Health
  7. Diagnostic Assays for early Lyme Borreliosis using in-vivo expressed antigens

    Amount: $1,655,122.00

    DESCRIPTION provided by applicant Current testing for Lyme disease is suboptimal because it requires two assay platforms including one with subjective interpretation of results and because it has ...

    SBIR Phase II 2014 Department of Health and Human Services National Institutes of Health
  8. A Multivalent Lyme Disease Vaccine Targeting Tick-Host-Pathogen Interactions

    Amount: $599,996.00

    DESCRIPTION provided by applicant This proposal seeks to develop a novel vaccine against Lyme disease by targeting Ixodes scapularis proteins critical for Borrelia burgdorferi transmission from ...

    STTR Phase I 2014 Department of Health and Human Services National Institutes of Health
  9. RNA Detection as an Improved Diagnostic Assay for Human Leptospirosis

    Amount: $600,000.00

    DESCRIPTION provided by applicant Leptospirosis a zoonotic disease is an important public health problem worldwide It is caused by spirochete bacteria belonging to nine species and more than ...

    STTR Phase I 2014 Department of Health and Human Services National Institutes of Health
  10. Small Molecule Antiviral Agents Against Flaviviruses

    Amount: $996,931.00

    Flaviviruses, and dengue viruses in particular, are significant human pathogens. No vaccine or specific therapeutic agent is available against West Nile and dengue viruses. Our goal is to develop pe ...

    SBIR Phase II 2013 Department of Defense Army

Agency Micro-sites

US Flag An Official Website of the United States Government